Cases & Deals

  • Home
  • Practices
  • AbbVie successfully faces off with Amgen in patent interference involving buffer-free antibody formulations

Share

AbbVie successfully faces off with Amgen in patent interference involving buffer-free antibody formulations

December 2017

Client(s) AbbVie Inc.

Jones Day represented AbbVie, Inc. in a patent interference against Amgen, Inc. before the PTAB involving the parties' applications/patents generally related to buffer-free antibody formulations, including formulations to adalimumab, marketed as HUMIRA®. On December 15, 2017, Gokarn (Amgen) conceded priority as to the invention in dispute. As a result, on December 20, 2017, the PTAB entered judgement against Gokarn (Amgen) in favor of Fraunhofer (AbbVie).

Fraunhofer (AbbVie) v. Gokarn (Amgen), Patent Interference No. 106,057 (PTAB 2016)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.